Pathogenic fungi like Candida albicans can cause oral, skin, nail and genital infections. While exposure to pathogenic fungi is generally not life-threatening, it can be deadly to immunocompromised patients with AIDS or cancer. A variety of antifungal medications, such as triazoles and polyenes, are currently used for treating fungal infections. The range of these antifungal medications, however, is extremely limited, with some fungal species developing resistance to these drugs.
Yi Yan Yang at the A*STAR Institute of Bioengineering and Nanotechnology in Singapore and co-workers, in collaboration with IBM Almaden Research Center in the United States, have discovered four cationic terephthalamide-bisurea compounds with strong antifungal activity, excellent microbial selectivity and low host toxicity. These small molecules can self-assemble into fibers, bind fungal membrane and rupture the cells of a variety of fungal species. The results may expand the possibilities of medication for battling drug-resistant fungal species.
Click "source" to read more.